Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
- 714 Downloads
Although recent reports indicate that K-ras mutation status is a biomarker that acts as a prognostic factor, only a few analyses of K-ras mutation subtypes have been published. In addition, there are no reports that analyze overall survival and prognostic factors according to K-ras mutation status and subtypes in only unresectable pancreatic cancer (PC) determined from tissues obtained by endoscopic ultrasound-guided fine-needle aspiration.
We retrospectively analyzed 242 patients who were diagnosed as having unresectable PC with available histological diagnosis. Clinical data collected included sex, age, Eastern Cooperative Oncology Group performance status, carbohydrate antigen (CA) 19-9, primary tumor location, stage (local or metastatic) according to TNM staging, first-line chemotherapy, K-ras mutation status and subtypes (G12D, G12V, and G12R), and overall survival. We analyzed the negative prognostic factors for reduced overall survival in unresectable PC patients using these data.
From multivariate analysis, CA19-9 ≥1000 U/ml (hazard ratio [HR] 1.78, 95 % confidence interval [CI] 1.28–2.46, P < 0.01), metastatic stage (HR 2.26, 95 % CI 1.58–3.24, P < 0.01), and mutant-K-ras (HR 1.76, 95 % CI 1.03–3.01, P = 0.04) were negative prognostic factors, indicating a reduced survival. Among the patients who had K-ras mutation subtypes, CA19-9 ≥1000 U/ml (HR 1.65, 95 % CI 1.12–2.37, P < 0.01), metastatic stage (HR 2.12, 95 % CI 1.44–3.14, P < 0.01), and the presence of the G12D or G12R mutations (HR 1.60, 95 % CI 1.11–2.28) were negative prognostic factors for overall survival.
K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients.
KeywordsK-ras mutation Subtype Pancreatic cancer EUS-FNA
Conflict of interest
The authors declare that they have no conflicts of interest.
- 8.Kullmann F, Hartmann A, Stohr R, Messmann H, Dollinger MM, Trojan J, et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology. 2011;81:3–8.PubMedCrossRefGoogle Scholar
- 11.Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89:469–74.PubMedCrossRefGoogle Scholar
- 20.Cox DR. Regression models and life-tables. J R Stat Soc B. 1984;34:588–91.Google Scholar
- 25.Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
- 30.Keohavong P, Demichele MAA, Melacrions AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas-relationship to prognosis. Clin Cancer Res. 1999;2:411–8.Google Scholar
- 31.John J, Frech M, Wittinghofer A. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation resection. J Biol Chem. 1998;263:792–9.Google Scholar
- 32.Krengle U, Schlichting L, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. J Biol Chem. 1989;264:86–92.Google Scholar